TFAP2D: A Potential Drug Target and Biomarker for Activating Enhancer-Binding Protein 2-Delta

Target Name: TFAP2D

NCBI ID: G83741

TFAP2D

TFAP2D: A Potential Drug Target and Biomarker for Activating Enhancer-Binding Protein 2-Delta

Abstract:

TFAP2D, a member of the TFAP family, has been identified as a potential drug target and biomarker for activating Enhancer-Binding Protein (EBP) 2-delta, a key regulator of gene expression and cancer progression. TFAP2D functions as a negative regulator of EBP 2-delta, thereby inhibiting its ability to enhance gene expression. This study aims to provide an in-depth analysis of TFAP2D as a drug target and biomarker, highlighting its potential clinical applications and future directions.

Introduction:

Gene expression regulation is a critical aspect of cell biology, and the process of gene expression control is tightly regulated by various factors, including transcription factors. Activating Enhancer-Binding Protein (EBP) 2-delta, a key regulator of gene expression and cancer progression, is a well-established process that plays a crucial role in cancer development. EBP 2-delta has been shown to promote the expression of various cancer-related genes, thereby contributing to tumorigenesis and metastasis.

TFAP2D, a member of the TFAP family, has been identified as a potential drug target and biomarker for activating EBP 2-delta. TFAP2D functions as a negative regulator of EBP 2-delta, thereby inhibiting its ability to enhance gene expression. This study aims to provide an in-depth analysis of TFAP2D as a drug target and biomarker, highlighting its potential clinical applications and future directions.

TFAP2D as a Drug Target:

TFAP2D has been shown to be a promising drug target for cancer therapy. Studies have shown that TFAP2D can inhibit the growth and spread of tumor cells by inhibiting the activity of EBP 2-delta to inhibit its promotion of gene expression. In addition, TFAP2D can also combine with alkylating agents to inhibit the cell cycle, extend cell life, and have significant anti-cancer effects.

TFAP2D as a biomarker:

TFAP2D can also serve as a biomarker to detect cancer progression and treatment efficacy. Since the activity of TFAP2D is affected by many factors, such as cell cycle, growth factors, DNA damage, etc., these factors can be used to detect its expression level to evaluate the effectiveness of tumor treatment. In addition, TFAP2D can also be used as a sensitive indicator of tumor progression and invasion, providing guidance for personalized treatment of tumor patients.

TFAP2D鈥檚 mechanism of action:

TFAP2D is a non-coding RNA whose function is to inhibit the activity of EBP 2-delta by binding to DNA. EBP 2-delta is a transcription factor that binds to DNA, thereby enhancing gene expression. Binding of TFAP2D leads to conformational changes in EBP 2-delta, thereby inhibiting its activity.

Interactions of TFAP2D:

Research shows that TFAP2D can interact with other proteins, thereby regulating their activity. Among them, TFAP2D interacts with histone 伪2 (H3A.2), thereby inhibiting its binding to DNA, thereby inhibiting the activity of EBP 2-未. In addition, TFAP2D can also bind to the DNA-binding protein DNMT, thereby inhibiting its methylation of DNA and further inhibiting the activity of EBP 2-未.

Clinical application prospects of TFAP2D:

As a new drug target, TFAP2D has broad application prospects. First, TFAP2D can be used as a target molecule for cancer therapy, inhibiting the growth and spread of tumor cells by inhibiting its activity. Secondly, TFAP2D can serve as a marker of tumor progression and invasion.

Protein Name: Transcription Factor AP-2 Delta

Functions: Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC (By similarity)

The "TFAP2D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TFAP2D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets